Sintx Technologies Crescita futura

Criteri Future verificati 1/6

Si prevede che gli utili di Sintx Technologies diminuiranno del 30% all'anno, mentre si prevede che il fatturato annuo crescerà del 7.6% all'anno. Si prevede che l'EPS diminuirà del 156.1% all'anno.

Informazioni chiave

-30.0%

Tasso di crescita degli utili

-156.13%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	13.4%
Tasso di crescita dei ricavi	7.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	20 Jun 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:1110 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	3	-14	N/A	-11	2
12/31/2024	3	-12	N/A	-11	2
6/30/2024	3	-9	-12	-11	N/A
3/31/2024	3	-9	-12	-12	N/A
12/31/2023	3	-8	-15	-14	N/A
9/30/2023	2	-14	-14	-13	N/A
6/30/2023	2	-14	-14	-13	N/A
3/31/2023	2	-14	-13	-12	N/A
12/31/2022	2	-16	-12	-10	N/A
9/30/2022	1	-10	-12	-11	N/A
6/30/2022	1	-10	-14	-11	N/A
3/31/2022	1	-10	-14	-10	N/A
12/31/2021	1	-9	-14	-10	N/A
9/30/2021	1	-9	-13	-10	N/A
6/30/2021	0	-9	-10	-10	N/A
3/31/2021	0	-11	-9	-9	N/A
12/31/2020	1	-17	-9	-9	N/A
9/30/2020	1	-16	-9	-9	N/A
6/30/2020	1	-15	-8	-8	N/A
3/31/2020	1	-14	-8	-8	N/A
12/31/2019	1	-7	-7	-6	N/A
9/30/2019	1	-8	-6	-6	N/A
6/30/2019	0	-15	-7	-7	N/A
3/31/2019	0	-22	-9	-9	N/A
12/31/2018	0	-24	-9	-9	N/A
9/30/2018	N/A	-24	-8	-8	N/A
6/30/2018	-6	-17	-7	-7	N/A
3/31/2018	-3	-9	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	4	-5	N/A	-6	N/A
6/30/2017	13	-15	N/A	-8	N/A
3/31/2017	14	-18	N/A	-8	N/A
12/31/2016	15	-21	N/A	-7	N/A
9/30/2016	17	-22	N/A	-7	N/A
6/30/2016	18	-21	N/A	-6	N/A
3/31/2016	19	-22	N/A	-8	N/A
12/31/2015	19	-24	N/A	-9	N/A
9/30/2015	20	-31	N/A	-10	N/A
6/30/2015	21	-26	N/A	-11	N/A
3/31/2015	22	-33	N/A	-15	N/A
12/31/2014	23	-33	N/A	-15	N/A
9/30/2014	23	-22	N/A	-16	N/A
6/30/2014	23	-20	N/A	-15	N/A
3/31/2014	23	-9	N/A	-11	N/A
12/31/2013	22	-8	N/A	-10	N/A
9/30/2013	23	-33	N/A	-9	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 1110 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 1110 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 1110 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 1110 ( 7.6% all'anno) crescerà più rapidamente del mercato German ( 6.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 1110 ( 7.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 1110 è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/08/21 06:41
Prezzo dell'azione a fine giornata	2024/05/24 00:00
Utili	2024/06/30
Utili annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Sintx Technologies, Inc. è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Edward Woo	Ascendiant Capital Markets LLC
David Turkaly	Citizens JMP Securities, LLC
Brandon Folkes	H.C. Wainwright & Co.

Sintx Technologies Crescita futura

Criteri Future verificati 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

No longer forecast to breakeven

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sintx Technologies, Inc. announced that it has received $4.5 million in funding

Sintx Technologies, Inc. Receives Nasdaq Notice Of Non-Compliance With Listing Rule 5550(b)(1)

Sintx Technologies, Inc. Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC Foot & Ankle Implant

Sintx Technologies, Inc. Announces Cessation of Eric Olson as President, Effective March 16, 2026

Sintx Technologies, Inc. Appoints Ryan Elmore as President, Effective March 16, 2026

SINTX Technologies, Inc. Announces Launch of OsseoSculpt an Advanced Biologic for Use with SINAPTIC Foot & Ankle Osteotomy Wedge System

SINTX Technologies, Inc. Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fibrous Materials

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $6.413876 million.

SINTX Technologies, Inc. Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

Sintx Technologies, Inc. Publishes Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride

SINTX Technologies, Inc. Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates

SINTX Technologies, Inc. Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

Sintx Technologies, Inc. Announces Executive Appointments

Sintx Technologies, Inc. Announces Board Changes

Sintx Technologies Announces Board Chairman Changes

Sintx Technologies, Inc. announced that it has received $5.000012 million in funding

Tethon Corporation acquired Technology Assessment & Transfer, Inc. from Sintx Technologies, Inc. (NasdaqCM:SINT).

Sintx Technologies, Inc. Appoints Eric K. Olson to the Board of Directors

Sintx Technologies, Inc.Appoints Gregg R. Honigblum as Chief Strategy Officer

Sintx Technologies, Inc., Annual General Meeting, Dec 19, 2024

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.11 loss in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Full year 2020 earnings released: US$1.01 loss per share (vs US$4.82 loss in FY 2019)

Sintx Technologies, Inc. Announces the Fabric Technology Shown to Inactivate Upon contact SARS-CoV-2, the Virus Causing the Covid-19 Pandemic